GlaxoSmithKline (JOBS) Says US Still Reviewing Clot Disorder Drug

WASHINGTON, Sept 19 (Reuters) - U.S. health officials still are reviewing GlaxoSmithKline Plc's proposed clotting disorder drug Promacta, the company said on Friday.
MORE ON THIS TOPIC